mAb Industry in China: Biosimilars vs. Innovative Biologics - Seguridad Mania.com - España y América Latina

Following patent cliffs for Erbitux, Rituxan, Sandosta_n and several big blockbusters, Herceptin, Avastin are now among the next biosimilar targets. This is creating huge potential for biosimilars, prompting innovators to shift their focus to target more emerging markets which remain untapped for many companies. In this presentation, Joe will be sharing with you his vision of the biosimilars market with a focus on China. He will also discuss key considerations for mAb and biologics therapeutic development, providing a broad overview of challenges and opportunities presenting in the market.   1.        Landscape changes of mAb therapeutics 2.        New targets and process/manufacturing innovation 3.        Key consideration of mAb industry in China 4.        Case study: Development strategies of PD-1 mAb as anti-tumor therapeutics in China for global market